Anna Edlund has 20 years of experience in microbial ecology and earned a Ph.D. in Microbiology at the Swedish University of Agricultural Sciences in Uppsala Sweden (2007). Anna held Postdoctoral fellowship positions at the Scripps Institution of Oceanography UCSD (2007-2010), where she studied ecology and evolution of small molecules, and at JCVI (2012-2016) where she was introduced to studies of the human microbiota. She was also a Staff Scientist at the School of Dentistry at UCLA (2014-2016) and an Assistant professor at JCVI (2016-2020). Anna holds an adjunct professorship at the Department of Pediatrics at UCSD since 2018.

Before re-joining JCVI in August this year, she worked as an R&D lead at a local microbiome company in Carlsbad. Her team was responsible for developing a stool microbiome self-collection kit with the goal to diagnose early stages of colorectal cancer.

Anna’s specific expertise is in the use of molecular and computational approaches (omics) to study complex microbial communities, such as those residing in the human oral cavity and the gut. As a scientist at JCVI Anna is exploring molecular mechanisms underlying a healthy gut microbiota. She is particularly interested in understanding the role of cooperative interactions between groups of closely related bacteria in gut health. Anna believes that a deeper knowledge of these mechanisms will provide knowledge on how to develop new therapeutics and prophylactic approaches, such as probiotics, that can prevent gut inflammation and other intestinal or systemic disease phenotypes.

Honors

President for the International Association for Dental Research, Clinical and Translational Research group (2019-2021).

The Young Scientist Award from Stockholm University the Marin Centrum, and the Royal Academy, Sweden (2011).

Research Priorities

Development of microbiome platform technology to enable advanced live biotherapeutics to treat human diseases. Target indications include Clostridium difficile infection (CDI), cancer treatment and inflammation indications related to microbiome dysbiosis.
  • Data science and engineering to define product candidates for target indications
  • Isolate, characterize and produce biomass for product candidate strains
  • Translational science to validate product candidates and enable regulatory path to commercialization

Publications

mucG, mucH, and mucI Modulate Production of Mutanocyclin and Reutericyclins in Streptococcus mutans B04Sm5.
Journal of bacteriology. 2022-04-11; e0004222.
PMID: 35404110
Tetramic Acids Mutanocyclin and Reutericyclin A, Produced by Streptococcus mutans Strain B04Sm5 Modulate the Ecology of an in vitro Oral Biofilm.
Frontiers in oral health. 2022-01-07; 2.796140.
PMID: 35048077
Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome.
International journal of molecular sciences. 2021-11-07; 22.21:
PMID: 34769481
Oral Microbial Species and Virulence Factors Associated with Oral Squamous Cell Carcinoma.
Microbial ecology. 2021-11-01; 82.4: 1030-1046.
PMID: 33155101
The Oral Host-Microbial Interactome: An Ecological Chronometer of Health?
Trends in microbiology. 2021-06-01; 29.6: 551-561.
PMID: 33279381
Deep metagenomics examines the oral microbiome during dental caries, revealing novel taxa and co-occurrences with host molecules.
Genome research. 2021-01-01; 31.1: 64-74.
PMID: 33239396
Identification of Oral Bacterial Biosynthetic Gene Clusters Associated with Caries.
Methods in molecular biology (Clifton, N.J.). 2021-01-01; 2327.161-189.
PMID: 34410645
Composite Long- and Short-Read Sequencing Delivers a Complete Genome Sequence of B04Sm5, a Reutericyclin- and Mutanocyclin-Producing Strain of Streptococcus mutans.
Microbiology resource announcements. 2020-11-19; 9.47:
PMID: 33214302
Caries-Associated Biosynthetic Gene Clusters in Streptococcus mutans.
Journal of dental research. 2020-07-01; 99.8: 969-976.
PMID: 32298190
Commensal Oral Rothia mucilaginosa Produces Enterobactin, a Metal-Chelating Siderophore.
mSystems. 2020-04-28; 5.2:
PMID: 32345739
Cariogenic Streptococcus mutans Produces Tetramic Acid Strain-Specific Antibiotics That Impair Commensal Colonization.
ACS infectious diseases. 2020-04-10; 6.4: 563-571.
PMID: 31906623
Establishing microbial composition measurement standards with reference frames.
Nature communications. 2019-06-20; 10.1: 2719.
PMID: 31222023
Klebsiella and Providencia emerge as lone survivors following long-term starvation of oral microbiota.
Proceedings of the National Academy of Sciences of the United States of America. 2019-04-23; 116.17: 8499-8504.
PMID: 30975748
Identification of the Bacterial Biosynthetic Gene Clusters of the Oral Microbiome Illuminates the Unexplored Social Language of Bacteria during Health and Disease.
mBio. 2019-04-16; 10.2:
PMID: 30992349
Exploiting the Oral Microbiome to Prevent Tooth Decay: Has Evolution Already Provided the Best Tools?
Frontiers in microbiology. 2019-01-11; 9.3323.
PMID: 30687294
Discovery of a Novel Periodontal Disease-Associated Bacterium.
Microbial ecology. 2019-01-01; 77.1: 267-276.
PMID: 29860637
Uncovering complex microbiome activities via metatranscriptomics during 24 hours of oral biofilm assembly and maturation.
Microbiome. 2018-12-06; 6.1: 217.
PMID: 30522530
Quorum Sensing Modulates the Epibiotic-Parasitic Relationship Between Actinomyces odontolyticus and Its Saccharibacteria epibiont, a Nanosynbacter lyticus Strain, TM7x.
Frontiers in microbiology. 2018-09-24; 9.2049.
PMID: 30319555
Targeted Antimicrobial Peptides: A Novel Technology to Eradicate Harmful Streptococcus Mutans.
Journal of the California Dental Association. 2017-10-01; 45.10: 557-564.
PMID: 29899655
Metabolic Fingerprints from the Human Oral Microbiome Reveal a Vast Knowledge Gap of Secreted Small Peptidic Molecules.
mSystems. 2017-07-18; 2.4:
PMID: 28761934
Uncovering the Horseshoe Effect in Microbial Analyses.
mSystems. 2017-02-21; 2.1:
PMID: 28251186
The Denture-Associated Oral Microbiome in Health and Stomatitis.
mSphere. 2016-12-28; 1.6:
PMID: 28066812
Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking.
Nature biotechnology. 2016-08-09; 34.8: 828-837.
PMID: 27504778
Metagenome and Metatranscriptome Analyses Using Protein Family Profiles.
PLoS computational biology. 2016-07-11; 12.7: e1004991.
PMID: 27400380
High-Quality Draft Genome Sequence of Low-pH-Active Veillonella parvula Strain SHI-1, Isolated from Human Saliva within an In Vitro Oral Biofilm Model.
Genome announcements. 2016-02-18; 4.1:
PMID: 26893419
Draft Genome Sequence of "Candidatus Bacteroides periocalifornicus," a New Member of the Bacteriodetes Phylum Found within the Oral Microbiome of Periodontitis Patients.
Genome announcements. 2015-12-23; 3.6:
PMID: 26701081
Meta-omics uncover temporal regulation of pathways across oral microbiome genera during in vitro sugar metabolism.
The ISME journal. 2015-12-01; 9.12: 2605-19.
PMID: 26023872
Bacteria-mediated effects of antibiotics on Daphnia nutrition.
Environmental science & technology. 2015-05-05; 49.9: 5779-87.
PMID: 25850437
Bacteriophage and their potential roles in the human oral cavity.
Journal of oral microbiology. 2015-04-09; 7.27423.
PMID: 25861745
Cultivation of a human-associated TM7 phylotype reveals a reduced genome and epibiotic parasitic lifestyle.
Proceedings of the National Academy of Sciences of the United States of America. 2015-01-06; 112.1: 244-9.
PMID: 25535390
An in vitro biofilm model system maintaining a highly reproducible species and metabolic diversity approaching that of the human oral microbiome.
Microbiome. 2013-10-02; 1.1: 25.
PMID: 24451062
Candidate phylum TM6 genome recovered from a hospital sink biofilm provides genomic insights into this uncultivated phylum.
Proceedings of the National Academy of Sciences of the United States of America. 2013-06-25; 110.26: E2390-9.
PMID: 23754396
Genome of the pathogen Porphyromonas gingivalis recovered from a biofilm in a hospital sink using a high-throughput single-cell genomics platform.
Genome research. 2013-05-01; 23.5: 867-77.
PMID: 23564253

Research Priorities

Development of microbiome platform technology to enable advanced live biotherapeutics to treat human diseases. Target indications include Clostridium difficile infection (CDI), cancer treatment and inflammation indications related to microbiome dysbiosis.
  • Data science and engineering to define product candidates for target indications
  • Isolate, characterize and produce biomass for product candidate strains
  • Translational science to validate product candidates and enable regulatory path to commercialization